Global Urokinase Injection Supply, Demand and Key Producers, 2026-2032
The global Urokinase Injection market size is expected to reach $ 486 million by 2032, rising at a market growth of 6.1% CAGR during the forecast period (2026-2032).
The urokinase injection market refers to the clinical and commercial use of injectable urokinase (urokinase for injection)?a ?clot-dissolving? medicine used in hospitals to break down unwanted blood clots. Urokinase works by acting on the body?s natural fibrinolytic system: it converts plasminogen into plasmin, and plasmin then breaks down fibrin clots (and also affects fibrinogen and some other plasma proteins). Because urokinase is given by injection/infusion and can cause serious bleeding, its use is typically limited to settings where doctors can monitor patients closely (emergency departments, intensive care units, catheter labs, interventional radiology suites, vascular surgery wards, and specialized stroke or thrombosis centers).
In practical terms, the market is defined by where and how urokinase injection is used. In some jurisdictions, product labeling and clinical practice include use for pulmonary embolism (blood clots in the lungs), for catheter-directed thrombolysis in peripheral arteries or graft occlusions, and for restoring patency of intravenous catheters blocked by clotted blood or fibrin. This ?hospital procedure drug? positioning is important: urokinase injection is not a long-term prevention drug like oral anticoagulants; it is more often a time-sensitive rescue therapy or a procedure-support drug used when a clot is already causing acute risk or blocking a device.
A key part of the market definition is also the dosage form and supply chain. Urokinase products are commonly supplied as a sterile lyophilized (freeze-dried) powder that must be reconstituted before use. These factors make urokinase different from many small-molecule injectables: producers must manage complex upstream cell culture, purification, sterile fill-finish, and strict quality control, and buyers care about lot consistency and supply reliability.
In 2025, global Urokinase Injection production reached approximately 15.6 million Units, with an average global market price of around US$ 20.1 per Units. The global single-line production capacity ranges from 350 to 500 K Units per year. The industry's gross profit margin is approximately 25%-35%.
On market trends, one broad trend is that thrombolysis is being shaped by newer thrombolytic agents, improved imaging, and more interventional procedures. In acute ischemic stroke, for example, many global guidelines focus on intravenous alteplase (and increasingly tenecteplase as an alternative in some systems) within defined time windows, and mechanical thrombectomy has expanded in selected patients. This matters for urokinase because it changes where urokinase is positioned: in many countries, urokinase is not the primary stroke thrombolytic, while in others it is used as a lower-cost or locally available option. A recent review notes that urokinase has been approved and used in China for years and that Chinese guidance has recommended intravenous urokinase within certain time windows for acute ischemic stroke, with commonly cited dosing ranges (for example 1,000,000?1,500,000 IU in that context). So, the stroke segment shows a ?two-track? trend: in some regions, practice is consolidating around rt-PA/tenecteplase and thrombectomy pathways, while in other regions, urokinase remains relevant due to access, cost, and local evidence bases.
A second trend is the growth of catheter use in modern medicine, which tends to expand the catheter-clearance opportunity for thrombolytics, including urokinase. Central venous catheters and other long-term lines are widely used for chemotherapy, parenteral nutrition, long courses of IV antibiotics, and repeated blood draws. The clinical literature describes catheter occlusion as a frequent complication and reviews thrombolytic options for restoring patency. In that review, several thrombolytic agents (including recombinant urokinase) are discussed with reported catheter clearance rates and time-to-clearance outcomes, and the paper also notes that thrombolytic prophylaxis in some studies reduced catheter occlusion incidence. Even if individual studies vary, the practical market implication is straightforward: as the number of patients dependent on long-term catheters rises (cancer care, home infusion, complex pediatrics, dialysis pathways), hospitals place higher value on reliable, fast methods to reopen lines and avoid line replacement procedures.
A third trend is a procedural shift toward targeted therapy in vascular care. For some vascular occlusions, clinicians may prefer catheter-directed approaches that localize treatment at the clot, often aiming to improve efficacy while limiting systemic exposure and bleeding risk. Urokinase has a history of use in catheter-directed settings (for example, peripheral arterial and graft thromboembolic occlusion described in product monographs). At the same time, competition is intense: other thrombolytics (alteplase, tenecteplase, reteplase in certain contexts) and mechanical strategies (aspiration, thrombectomy devices, angioplasty/stenting) all influence whether a hospital uses urokinase, which dose, and for which patients. This competitive pressure pushes the urokinase market toward niches where it has clear operational or economic advantages (availability, protocol familiarity, cost, or suitability for a specific catheter-clearance workflow).
This report studies the global Urokinase Injection production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Urokinase Injection and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Urokinase Injection that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Urokinase Injection total production and demand, 2021-2032, (K Units)
Global Urokinase Injection total production value, 2021-2032, (USD Million)
Global Urokinase Injection production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global Urokinase Injection consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: Urokinase Injection domestic production, consumption, key domestic manufacturers and share
Global Urokinase Injection production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global Urokinase Injection production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global Urokinase Injection production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Urokinase Injection market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Syner-Med, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, Techpool, Microbic Biosystems, LIVZON, Wuhan Humanwell Pharma, Tianjin Biochem Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Urokinase Injection market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Urokinase Injection Market, By Region:
1. How big is the global Urokinase Injection market?
2. What is the demand of the global Urokinase Injection market?
3. What is the year over year growth of the global Urokinase Injection market?
4. What is the production and production value of the global Urokinase Injection market?
5. Who are the key producers in the global Urokinase Injection market?
6. What are the growth factors driving the market demand?
The urokinase injection market refers to the clinical and commercial use of injectable urokinase (urokinase for injection)?a ?clot-dissolving? medicine used in hospitals to break down unwanted blood clots. Urokinase works by acting on the body?s natural fibrinolytic system: it converts plasminogen into plasmin, and plasmin then breaks down fibrin clots (and also affects fibrinogen and some other plasma proteins). Because urokinase is given by injection/infusion and can cause serious bleeding, its use is typically limited to settings where doctors can monitor patients closely (emergency departments, intensive care units, catheter labs, interventional radiology suites, vascular surgery wards, and specialized stroke or thrombosis centers).
In practical terms, the market is defined by where and how urokinase injection is used. In some jurisdictions, product labeling and clinical practice include use for pulmonary embolism (blood clots in the lungs), for catheter-directed thrombolysis in peripheral arteries or graft occlusions, and for restoring patency of intravenous catheters blocked by clotted blood or fibrin. This ?hospital procedure drug? positioning is important: urokinase injection is not a long-term prevention drug like oral anticoagulants; it is more often a time-sensitive rescue therapy or a procedure-support drug used when a clot is already causing acute risk or blocking a device.
A key part of the market definition is also the dosage form and supply chain. Urokinase products are commonly supplied as a sterile lyophilized (freeze-dried) powder that must be reconstituted before use. These factors make urokinase different from many small-molecule injectables: producers must manage complex upstream cell culture, purification, sterile fill-finish, and strict quality control, and buyers care about lot consistency and supply reliability.
In 2025, global Urokinase Injection production reached approximately 15.6 million Units, with an average global market price of around US$ 20.1 per Units. The global single-line production capacity ranges from 350 to 500 K Units per year. The industry's gross profit margin is approximately 25%-35%.
On market trends, one broad trend is that thrombolysis is being shaped by newer thrombolytic agents, improved imaging, and more interventional procedures. In acute ischemic stroke, for example, many global guidelines focus on intravenous alteplase (and increasingly tenecteplase as an alternative in some systems) within defined time windows, and mechanical thrombectomy has expanded in selected patients. This matters for urokinase because it changes where urokinase is positioned: in many countries, urokinase is not the primary stroke thrombolytic, while in others it is used as a lower-cost or locally available option. A recent review notes that urokinase has been approved and used in China for years and that Chinese guidance has recommended intravenous urokinase within certain time windows for acute ischemic stroke, with commonly cited dosing ranges (for example 1,000,000?1,500,000 IU in that context). So, the stroke segment shows a ?two-track? trend: in some regions, practice is consolidating around rt-PA/tenecteplase and thrombectomy pathways, while in other regions, urokinase remains relevant due to access, cost, and local evidence bases.
A second trend is the growth of catheter use in modern medicine, which tends to expand the catheter-clearance opportunity for thrombolytics, including urokinase. Central venous catheters and other long-term lines are widely used for chemotherapy, parenteral nutrition, long courses of IV antibiotics, and repeated blood draws. The clinical literature describes catheter occlusion as a frequent complication and reviews thrombolytic options for restoring patency. In that review, several thrombolytic agents (including recombinant urokinase) are discussed with reported catheter clearance rates and time-to-clearance outcomes, and the paper also notes that thrombolytic prophylaxis in some studies reduced catheter occlusion incidence. Even if individual studies vary, the practical market implication is straightforward: as the number of patients dependent on long-term catheters rises (cancer care, home infusion, complex pediatrics, dialysis pathways), hospitals place higher value on reliable, fast methods to reopen lines and avoid line replacement procedures.
A third trend is a procedural shift toward targeted therapy in vascular care. For some vascular occlusions, clinicians may prefer catheter-directed approaches that localize treatment at the clot, often aiming to improve efficacy while limiting systemic exposure and bleeding risk. Urokinase has a history of use in catheter-directed settings (for example, peripheral arterial and graft thromboembolic occlusion described in product monographs). At the same time, competition is intense: other thrombolytics (alteplase, tenecteplase, reteplase in certain contexts) and mechanical strategies (aspiration, thrombectomy devices, angioplasty/stenting) all influence whether a hospital uses urokinase, which dose, and for which patients. This competitive pressure pushes the urokinase market toward niches where it has clear operational or economic advantages (availability, protocol familiarity, cost, or suitability for a specific catheter-clearance workflow).
This report studies the global Urokinase Injection production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Urokinase Injection and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Urokinase Injection that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Urokinase Injection total production and demand, 2021-2032, (K Units)
Global Urokinase Injection total production value, 2021-2032, (USD Million)
Global Urokinase Injection production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global Urokinase Injection consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: Urokinase Injection domestic production, consumption, key domestic manufacturers and share
Global Urokinase Injection production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global Urokinase Injection production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global Urokinase Injection production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Urokinase Injection market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Syner-Med, Wanhua Biochem, Jiangxi Haoran Bio-Pharma, Jiangsu Aidea Pharmaceutical, Techpool, Microbic Biosystems, LIVZON, Wuhan Humanwell Pharma, Tianjin Biochem Pharma, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Urokinase Injection market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Urokinase Injection Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- 10000-100000IU
- 100000-1000000IU
- Others
- Pulmonary Embolism Thrombolysis
- Deep Vein Thrombosis
- Peripheral Arterial Occlusion Thrombolysis
- Catheter / Cannula Occlusion Clearance
- Others
- Systemic Infusion
- Catheter-directed Thrombolysis (CDT)
- Intracatheter Dwell / Lock Technique
- Standard Clinical Grade
- High-purity / Low-impurity Grade
- Low Endotoxin / Low Bioburden Specifications
- Hospital
- Clinic
- Others
- Syner-Med
- Wanhua Biochem
- Jiangxi Haoran Bio-Pharma
- Jiangsu Aidea Pharmaceutical
- Techpool
- Microbic Biosystems
- LIVZON
- Wuhan Humanwell Pharma
- Tianjin Biochem Pharma
1. How big is the global Urokinase Injection market?
2. What is the demand of the global Urokinase Injection market?
3. What is the year over year growth of the global Urokinase Injection market?
4. What is the production and production value of the global Urokinase Injection market?
5. Who are the key producers in the global Urokinase Injection market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Urokinase Injection Introduction
1.2 World Urokinase Injection Supply & Forecast
1.2.1 World Urokinase Injection Production Value (2021 & 2025 & 2032)
1.2.2 World Urokinase Injection Production (2021-2032)
1.2.3 World Urokinase Injection Pricing Trends (2021-2032)
1.3 World Urokinase Injection Production by Region (Based on Production Site)
1.3.1 World Urokinase Injection Production Value by Region (2021-2032)
1.3.2 World Urokinase Injection Production by Region (2021-2032)
1.3.3 World Urokinase Injection Average Price by Region (2021-2032)
1.3.4 North America Urokinase Injection Production (2021-2032)
1.3.5 Europe Urokinase Injection Production (2021-2032)
1.3.6 China Urokinase Injection Production (2021-2032)
1.3.7 Japan Urokinase Injection Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Urokinase Injection Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Urokinase Injection Major Market Trends
2 DEMAND SUMMARY
2.1 World Urokinase Injection Demand (2021-2032)
2.2 World Urokinase Injection Consumption by Region
2.2.1 World Urokinase Injection Consumption by Region (2021-2026)
2.2.2 World Urokinase Injection Consumption Forecast by Region (2027-2032)
2.3 United States Urokinase Injection Consumption (2021-2032)
2.4 China Urokinase Injection Consumption (2021-2032)
2.5 Europe Urokinase Injection Consumption (2021-2032)
2.6 Japan Urokinase Injection Consumption (2021-2032)
2.7 South Korea Urokinase Injection Consumption (2021-2032)
2.8 ASEAN Urokinase Injection Consumption (2021-2032)
2.9 India Urokinase Injection Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Urokinase Injection Production Value by Manufacturer (2021-2026)
3.2 World Urokinase Injection Production by Manufacturer (2021-2026)
3.3 World Urokinase Injection Average Price by Manufacturer (2021-2026)
3.4 Urokinase Injection Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Urokinase Injection Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Urokinase Injection in 2025
3.5.3 Global Concentration Ratios (CR8) for Urokinase Injection in 2025
3.6 Urokinase Injection Market: Overall Company Footprint Analysis
3.6.1 Urokinase Injection Market: Region Footprint
3.6.2 Urokinase Injection Market: Company Product Type Footprint
3.6.3 Urokinase Injection Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Urokinase Injection Production Value Comparison
4.1.1 United States VS China: Urokinase Injection Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Urokinase Injection Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Urokinase Injection Production Comparison
4.2.1 United States VS China: Urokinase Injection Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Urokinase Injection Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Urokinase Injection Consumption Comparison
4.3.1 United States VS China: Urokinase Injection Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Urokinase Injection Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Urokinase Injection Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Urokinase Injection Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Urokinase Injection Production Value (2021-2026)
4.4.3 United States Based Manufacturers Urokinase Injection Production (2021-2026)
4.5 China Based Urokinase Injection Manufacturers and Market Share
4.5.1 China Based Urokinase Injection Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Urokinase Injection Production Value (2021-2026)
4.5.3 China Based Manufacturers Urokinase Injection Production (2021-2026)
4.6 Rest of World Based Urokinase Injection Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Urokinase Injection Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Urokinase Injection Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Urokinase Injection Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Urokinase Injection Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 10000-100000IU
5.2.2 100000-1000000IU
5.2.3 Others
5.3 Market Segment by Type
5.3.1 World Urokinase Injection Production by Type (2021-2032)
5.3.2 World Urokinase Injection Production Value by Type (2021-2032)
5.3.3 World Urokinase Injection Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY CLINICAL USE
6.1 World Urokinase Injection Market Size Overview by Clinical Use: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Clinical Use
6.2.1 Pulmonary Embolism Thrombolysis
6.2.2 Deep Vein Thrombosis
6.2.3 Peripheral Arterial Occlusion Thrombolysis
6.2.4 Catheter / Cannula Occlusion Clearance
6.2.5 Others
6.3 Market Segment by Clinical Use
6.3.1 World Urokinase Injection Production by Clinical Use (2021-2032)
6.3.2 World Urokinase Injection Production Value by Clinical Use (2021-2032)
6.3.3 World Urokinase Injection Average Price by Clinical Use (2021-2032)
7 MARKET ANALYSIS BY ADMINISTRATION APPROACH
7.1 World Urokinase Injection Market Size Overview by Administration Approach: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Administration Approach
7.2.1 Systemic Infusion
7.2.2 Catheter-directed Thrombolysis (CDT)
7.2.3 Intracatheter Dwell / Lock Technique
7.3 Market Segment by Administration Approach
7.3.1 World Urokinase Injection Production by Administration Approach (2021-2032)
7.3.2 World Urokinase Injection Production Value by Administration Approach (2021-2032)
7.3.3 World Urokinase Injection Average Price by Administration Approach (2021-2032)
8 MARKET ANALYSIS BY PURITY
8.1 World Urokinase Injection Market Size Overview by Purity: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Purity
8.2.1 Standard Clinical Grade
8.2.2 High-purity / Low-impurity Grade
8.2.3 Low Endotoxin / Low Bioburden Specifications
8.3 Market Segment by Purity
8.3.1 World Urokinase Injection Production by Purity (2021-2032)
8.3.2 World Urokinase Injection Production Value by Purity (2021-2032)
8.3.3 World Urokinase Injection Average Price by Purity (2021-2032)
9 MARKET ANALYSIS BY APPLICATION
9.1 World Urokinase Injection Market Size Overview by Application: 2021 VS 2025 VS 2032
9.2 Segment Introduction by Application
9.2.1 Hospital
9.2.2 Clinic
9.2.3 Others
9.3 Market Segment by Application
9.3.1 World Urokinase Injection Production by Application (2021-2032)
9.3.2 World Urokinase Injection Production Value by Application (2021-2032)
9.3.3 World Urokinase Injection Average Price by Application (2021-2032)
10 COMPANY PROFILES
10.1 Syner-Med
10.1.1 Syner-Med Details
10.1.2 Syner-Med Major Business
10.1.3 Syner-Med Urokinase Injection Product and Services
10.1.4 Syner-Med Urokinase Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.1.5 Syner-Med Recent Developments/Updates
10.1.6 Syner-Med Competitive Strengths & Weaknesses
10.2 Wanhua Biochem
10.2.1 Wanhua Biochem Details
10.2.2 Wanhua Biochem Major Business
10.2.3 Wanhua Biochem Urokinase Injection Product and Services
10.2.4 Wanhua Biochem Urokinase Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.2.5 Wanhua Biochem Recent Developments/Updates
10.2.6 Wanhua Biochem Competitive Strengths & Weaknesses
10.3 Jiangxi Haoran Bio-Pharma
10.3.1 Jiangxi Haoran Bio-Pharma Details
10.3.2 Jiangxi Haoran Bio-Pharma Major Business
10.3.3 Jiangxi Haoran Bio-Pharma Urokinase Injection Product and Services
10.3.4 Jiangxi Haoran Bio-Pharma Urokinase Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.3.5 Jiangxi Haoran Bio-Pharma Recent Developments/Updates
10.3.6 Jiangxi Haoran Bio-Pharma Competitive Strengths & Weaknesses
10.4 Jiangsu Aidea Pharmaceutical
10.4.1 Jiangsu Aidea Pharmaceutical Details
10.4.2 Jiangsu Aidea Pharmaceutical Major Business
10.4.3 Jiangsu Aidea Pharmaceutical Urokinase Injection Product and Services
10.4.4 Jiangsu Aidea Pharmaceutical Urokinase Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.4.5 Jiangsu Aidea Pharmaceutical Recent Developments/Updates
10.4.6 Jiangsu Aidea Pharmaceutical Competitive Strengths & Weaknesses
10.5 Techpool
10.5.1 Techpool Details
10.5.2 Techpool Major Business
10.5.3 Techpool Urokinase Injection Product and Services
10.5.4 Techpool Urokinase Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.5.5 Techpool Recent Developments/Updates
10.5.6 Techpool Competitive Strengths & Weaknesses
10.6 Microbic Biosystems
10.6.1 Microbic Biosystems Details
10.6.2 Microbic Biosystems Major Business
10.6.3 Microbic Biosystems Urokinase Injection Product and Services
10.6.4 Microbic Biosystems Urokinase Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.6.5 Microbic Biosystems Recent Developments/Updates
10.6.6 Microbic Biosystems Competitive Strengths & Weaknesses
10.7 LIVZON
10.7.1 LIVZON Details
10.7.2 LIVZON Major Business
10.7.3 LIVZON Urokinase Injection Product and Services
10.7.4 LIVZON Urokinase Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.7.5 LIVZON Recent Developments/Updates
10.7.6 LIVZON Competitive Strengths & Weaknesses
10.8 Wuhan Humanwell Pharma
10.8.1 Wuhan Humanwell Pharma Details
10.8.2 Wuhan Humanwell Pharma Major Business
10.8.3 Wuhan Humanwell Pharma Urokinase Injection Product and Services
10.8.4 Wuhan Humanwell Pharma Urokinase Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.8.5 Wuhan Humanwell Pharma Recent Developments/Updates
10.8.6 Wuhan Humanwell Pharma Competitive Strengths & Weaknesses
10.9 Tianjin Biochem Pharma
10.9.1 Tianjin Biochem Pharma Details
10.9.2 Tianjin Biochem Pharma Major Business
10.9.3 Tianjin Biochem Pharma Urokinase Injection Product and Services
10.9.4 Tianjin Biochem Pharma Urokinase Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.9.5 Tianjin Biochem Pharma Recent Developments/Updates
10.9.6 Tianjin Biochem Pharma Competitive Strengths & Weaknesses
11 INDUSTRY CHAIN ANALYSIS
11.1 Urokinase Injection Industry Chain
11.2 Urokinase Injection Upstream Analysis
11.2.1 Urokinase Injection Core Raw Materials
11.2.2 Main Manufacturers of Urokinase Injection Core Raw Materials
11.3 Midstream Analysis
11.4 Downstream Analysis
11.5 Urokinase Injection Production Mode
11.6 Urokinase Injection Procurement Model
11.7 Urokinase Injection Industry Sales Model and Sales Channels
11.7.1 Urokinase Injection Sales Model
11.7.2 Urokinase Injection Typical Distributors
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology
13.2 Research Process and Data Source
13.3 Disclaimer
1.1 Urokinase Injection Introduction
1.2 World Urokinase Injection Supply & Forecast
1.2.1 World Urokinase Injection Production Value (2021 & 2025 & 2032)
1.2.2 World Urokinase Injection Production (2021-2032)
1.2.3 World Urokinase Injection Pricing Trends (2021-2032)
1.3 World Urokinase Injection Production by Region (Based on Production Site)
1.3.1 World Urokinase Injection Production Value by Region (2021-2032)
1.3.2 World Urokinase Injection Production by Region (2021-2032)
1.3.3 World Urokinase Injection Average Price by Region (2021-2032)
1.3.4 North America Urokinase Injection Production (2021-2032)
1.3.5 Europe Urokinase Injection Production (2021-2032)
1.3.6 China Urokinase Injection Production (2021-2032)
1.3.7 Japan Urokinase Injection Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Urokinase Injection Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Urokinase Injection Major Market Trends
2 DEMAND SUMMARY
2.1 World Urokinase Injection Demand (2021-2032)
2.2 World Urokinase Injection Consumption by Region
2.2.1 World Urokinase Injection Consumption by Region (2021-2026)
2.2.2 World Urokinase Injection Consumption Forecast by Region (2027-2032)
2.3 United States Urokinase Injection Consumption (2021-2032)
2.4 China Urokinase Injection Consumption (2021-2032)
2.5 Europe Urokinase Injection Consumption (2021-2032)
2.6 Japan Urokinase Injection Consumption (2021-2032)
2.7 South Korea Urokinase Injection Consumption (2021-2032)
2.8 ASEAN Urokinase Injection Consumption (2021-2032)
2.9 India Urokinase Injection Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Urokinase Injection Production Value by Manufacturer (2021-2026)
3.2 World Urokinase Injection Production by Manufacturer (2021-2026)
3.3 World Urokinase Injection Average Price by Manufacturer (2021-2026)
3.4 Urokinase Injection Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Urokinase Injection Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Urokinase Injection in 2025
3.5.3 Global Concentration Ratios (CR8) for Urokinase Injection in 2025
3.6 Urokinase Injection Market: Overall Company Footprint Analysis
3.6.1 Urokinase Injection Market: Region Footprint
3.6.2 Urokinase Injection Market: Company Product Type Footprint
3.6.3 Urokinase Injection Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Urokinase Injection Production Value Comparison
4.1.1 United States VS China: Urokinase Injection Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Urokinase Injection Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Urokinase Injection Production Comparison
4.2.1 United States VS China: Urokinase Injection Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Urokinase Injection Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Urokinase Injection Consumption Comparison
4.3.1 United States VS China: Urokinase Injection Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Urokinase Injection Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Urokinase Injection Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Urokinase Injection Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Urokinase Injection Production Value (2021-2026)
4.4.3 United States Based Manufacturers Urokinase Injection Production (2021-2026)
4.5 China Based Urokinase Injection Manufacturers and Market Share
4.5.1 China Based Urokinase Injection Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Urokinase Injection Production Value (2021-2026)
4.5.3 China Based Manufacturers Urokinase Injection Production (2021-2026)
4.6 Rest of World Based Urokinase Injection Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Urokinase Injection Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Urokinase Injection Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Urokinase Injection Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Urokinase Injection Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 10000-100000IU
5.2.2 100000-1000000IU
5.2.3 Others
5.3 Market Segment by Type
5.3.1 World Urokinase Injection Production by Type (2021-2032)
5.3.2 World Urokinase Injection Production Value by Type (2021-2032)
5.3.3 World Urokinase Injection Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY CLINICAL USE
6.1 World Urokinase Injection Market Size Overview by Clinical Use: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Clinical Use
6.2.1 Pulmonary Embolism Thrombolysis
6.2.2 Deep Vein Thrombosis
6.2.3 Peripheral Arterial Occlusion Thrombolysis
6.2.4 Catheter / Cannula Occlusion Clearance
6.2.5 Others
6.3 Market Segment by Clinical Use
6.3.1 World Urokinase Injection Production by Clinical Use (2021-2032)
6.3.2 World Urokinase Injection Production Value by Clinical Use (2021-2032)
6.3.3 World Urokinase Injection Average Price by Clinical Use (2021-2032)
7 MARKET ANALYSIS BY ADMINISTRATION APPROACH
7.1 World Urokinase Injection Market Size Overview by Administration Approach: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Administration Approach
7.2.1 Systemic Infusion
7.2.2 Catheter-directed Thrombolysis (CDT)
7.2.3 Intracatheter Dwell / Lock Technique
7.3 Market Segment by Administration Approach
7.3.1 World Urokinase Injection Production by Administration Approach (2021-2032)
7.3.2 World Urokinase Injection Production Value by Administration Approach (2021-2032)
7.3.3 World Urokinase Injection Average Price by Administration Approach (2021-2032)
8 MARKET ANALYSIS BY PURITY
8.1 World Urokinase Injection Market Size Overview by Purity: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Purity
8.2.1 Standard Clinical Grade
8.2.2 High-purity / Low-impurity Grade
8.2.3 Low Endotoxin / Low Bioburden Specifications
8.3 Market Segment by Purity
8.3.1 World Urokinase Injection Production by Purity (2021-2032)
8.3.2 World Urokinase Injection Production Value by Purity (2021-2032)
8.3.3 World Urokinase Injection Average Price by Purity (2021-2032)
9 MARKET ANALYSIS BY APPLICATION
9.1 World Urokinase Injection Market Size Overview by Application: 2021 VS 2025 VS 2032
9.2 Segment Introduction by Application
9.2.1 Hospital
9.2.2 Clinic
9.2.3 Others
9.3 Market Segment by Application
9.3.1 World Urokinase Injection Production by Application (2021-2032)
9.3.2 World Urokinase Injection Production Value by Application (2021-2032)
9.3.3 World Urokinase Injection Average Price by Application (2021-2032)
10 COMPANY PROFILES
10.1 Syner-Med
10.1.1 Syner-Med Details
10.1.2 Syner-Med Major Business
10.1.3 Syner-Med Urokinase Injection Product and Services
10.1.4 Syner-Med Urokinase Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.1.5 Syner-Med Recent Developments/Updates
10.1.6 Syner-Med Competitive Strengths & Weaknesses
10.2 Wanhua Biochem
10.2.1 Wanhua Biochem Details
10.2.2 Wanhua Biochem Major Business
10.2.3 Wanhua Biochem Urokinase Injection Product and Services
10.2.4 Wanhua Biochem Urokinase Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.2.5 Wanhua Biochem Recent Developments/Updates
10.2.6 Wanhua Biochem Competitive Strengths & Weaknesses
10.3 Jiangxi Haoran Bio-Pharma
10.3.1 Jiangxi Haoran Bio-Pharma Details
10.3.2 Jiangxi Haoran Bio-Pharma Major Business
10.3.3 Jiangxi Haoran Bio-Pharma Urokinase Injection Product and Services
10.3.4 Jiangxi Haoran Bio-Pharma Urokinase Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.3.5 Jiangxi Haoran Bio-Pharma Recent Developments/Updates
10.3.6 Jiangxi Haoran Bio-Pharma Competitive Strengths & Weaknesses
10.4 Jiangsu Aidea Pharmaceutical
10.4.1 Jiangsu Aidea Pharmaceutical Details
10.4.2 Jiangsu Aidea Pharmaceutical Major Business
10.4.3 Jiangsu Aidea Pharmaceutical Urokinase Injection Product and Services
10.4.4 Jiangsu Aidea Pharmaceutical Urokinase Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.4.5 Jiangsu Aidea Pharmaceutical Recent Developments/Updates
10.4.6 Jiangsu Aidea Pharmaceutical Competitive Strengths & Weaknesses
10.5 Techpool
10.5.1 Techpool Details
10.5.2 Techpool Major Business
10.5.3 Techpool Urokinase Injection Product and Services
10.5.4 Techpool Urokinase Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.5.5 Techpool Recent Developments/Updates
10.5.6 Techpool Competitive Strengths & Weaknesses
10.6 Microbic Biosystems
10.6.1 Microbic Biosystems Details
10.6.2 Microbic Biosystems Major Business
10.6.3 Microbic Biosystems Urokinase Injection Product and Services
10.6.4 Microbic Biosystems Urokinase Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.6.5 Microbic Biosystems Recent Developments/Updates
10.6.6 Microbic Biosystems Competitive Strengths & Weaknesses
10.7 LIVZON
10.7.1 LIVZON Details
10.7.2 LIVZON Major Business
10.7.3 LIVZON Urokinase Injection Product and Services
10.7.4 LIVZON Urokinase Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.7.5 LIVZON Recent Developments/Updates
10.7.6 LIVZON Competitive Strengths & Weaknesses
10.8 Wuhan Humanwell Pharma
10.8.1 Wuhan Humanwell Pharma Details
10.8.2 Wuhan Humanwell Pharma Major Business
10.8.3 Wuhan Humanwell Pharma Urokinase Injection Product and Services
10.8.4 Wuhan Humanwell Pharma Urokinase Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.8.5 Wuhan Humanwell Pharma Recent Developments/Updates
10.8.6 Wuhan Humanwell Pharma Competitive Strengths & Weaknesses
10.9 Tianjin Biochem Pharma
10.9.1 Tianjin Biochem Pharma Details
10.9.2 Tianjin Biochem Pharma Major Business
10.9.3 Tianjin Biochem Pharma Urokinase Injection Product and Services
10.9.4 Tianjin Biochem Pharma Urokinase Injection Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.9.5 Tianjin Biochem Pharma Recent Developments/Updates
10.9.6 Tianjin Biochem Pharma Competitive Strengths & Weaknesses
11 INDUSTRY CHAIN ANALYSIS
11.1 Urokinase Injection Industry Chain
11.2 Urokinase Injection Upstream Analysis
11.2.1 Urokinase Injection Core Raw Materials
11.2.2 Main Manufacturers of Urokinase Injection Core Raw Materials
11.3 Midstream Analysis
11.4 Downstream Analysis
11.5 Urokinase Injection Production Mode
11.6 Urokinase Injection Procurement Model
11.7 Urokinase Injection Industry Sales Model and Sales Channels
11.7.1 Urokinase Injection Sales Model
11.7.2 Urokinase Injection Typical Distributors
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology
13.2 Research Process and Data Source
13.3 Disclaimer
LIST OF TABLES
Table 1. World Urokinase Injection Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Urokinase Injection Production Value by Region (2021-2026) & (USD Million)
Table 3. World Urokinase Injection Production Value by Region (2027-2032) & (USD Million)
Table 4. World Urokinase Injection Production Value Market Share by Region (2021-2026)
Table 5. World Urokinase Injection Production Value Market Share by Region (2027-2032)
Table 6. World Urokinase Injection Production by Region (2021-2026) & (K Units)
Table 7. World Urokinase Injection Production by Region (2027-2032) & (K Units)
Table 8. World Urokinase Injection Production Market Share by Region (2021-2026)
Table 9. World Urokinase Injection Production Market Share by Region (2027-2032)
Table 10. World Urokinase Injection Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World Urokinase Injection Average Price by Region (2027-2032) & (US$/Unit)
Table 12. Urokinase Injection Major Market Trends
Table 13. World Urokinase Injection Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World Urokinase Injection Consumption by Region (2021-2026) & (K Units)
Table 15. World Urokinase Injection Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World Urokinase Injection Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Urokinase Injection Producers in 2025
Table 18. World Urokinase Injection Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key Urokinase Injection Producers in 2025
Table 20. World Urokinase Injection Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global Urokinase Injection Company Evaluation Quadrant
Table 22. World Urokinase Injection Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Urokinase Injection Production Site of Key Manufacturer
Table 24. Urokinase Injection Market: Company Product Type Footprint
Table 25. Urokinase Injection Market: Company Product Application Footprint
Table 26. Urokinase Injection Competitive Factors
Table 27. Urokinase Injection New Entrant and Capacity Expansion Plans
Table 28. Urokinase Injection Mergers & Acquisitions Activity
Table 29. United States VS China Urokinase Injection Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Urokinase Injection Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China Urokinase Injection Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based Urokinase Injection Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Urokinase Injection Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Urokinase Injection Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Urokinase Injection Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers Urokinase Injection Production Market Share (2021-2026)
Table 37. China Based Urokinase Injection Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Urokinase Injection Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Urokinase Injection Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Urokinase Injection Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers Urokinase Injection Production Market Share (2021-2026)
Table 42. Rest of World Based Urokinase Injection Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Urokinase Injection Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Urokinase Injection Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Urokinase Injection Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers Urokinase Injection Production Market Share (2021-2026)
Table 47. World Urokinase Injection Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Urokinase Injection Production by Type (2021-2026) & (K Units)
Table 49. World Urokinase Injection Production by Type (2027-2032) & (K Units)
Table 50. World Urokinase Injection Production Value by Type (2021-2026) & (USD Million)
Table 51. World Urokinase Injection Production Value by Type (2027-2032) & (USD Million)
Table 52. World Urokinase Injection Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World Urokinase Injection Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World Urokinase Injection Production Value by Clinical Use, (USD Million), 2021 & 2025 & 2032
Table 55. World Urokinase Injection Production by Clinical Use (2021-2026) & (K Units)
Table 56. World Urokinase Injection Production by Clinical Use (2027-2032) & (K Units)
Table 57. World Urokinase Injection Production Value by Clinical Use (2021-2026) & (USD Million)
Table 58. World Urokinase Injection Production Value by Clinical Use (2027-2032) & (USD Million)
Table 59. World Urokinase Injection Average Price by Clinical Use (2021-2026) & (US$/Unit)
Table 60. World Urokinase Injection Average Price by Clinical Use (2027-2032) & (US$/Unit)
Table 61. World Urokinase Injection Production Value by Administration Approach, (USD Million), 2021 & 2025 & 2032
Table 62. World Urokinase Injection Production by Administration Approach (2021-2026) & (K Units)
Table 63. World Urokinase Injection Production by Administration Approach (2027-2032) & (K Units)
Table 64. World Urokinase Injection Production Value by Administration Approach (2021-2026) & (USD Million)
Table 65. World Urokinase Injection Production Value by Administration Approach (2027-2032) & (USD Million)
Table 66. World Urokinase Injection Average Price by Administration Approach (2021-2026) & (US$/Unit)
Table 67. World Urokinase Injection Average Price by Administration Approach (2027-2032) & (US$/Unit)
Table 68. World Urokinase Injection Production Value by Purity, (USD Million), 2021 & 2025 & 2032
Table 69. World Urokinase Injection Production by Purity (2021-2026) & (K Units)
Table 70. World Urokinase Injection Production by Purity (2027-2032) & (K Units)
Table 71. World Urokinase Injection Production Value by Purity (2021-2026) & (USD Million)
Table 72. World Urokinase Injection Production Value by Purity (2027-2032) & (USD Million)
Table 73. World Urokinase Injection Average Price by Purity (2021-2026) & (US$/Unit)
Table 74. World Urokinase Injection Average Price by Purity (2027-2032) & (US$/Unit)
Table 75. World Urokinase Injection Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 76. World Urokinase Injection Production by Application (2021-2026) & (K Units)
Table 77. World Urokinase Injection Production by Application (2027-2032) & (K Units)
Table 78. World Urokinase Injection Production Value by Application (2021-2026) & (USD Million)
Table 79. World Urokinase Injection Production Value by Application (2027-2032) & (USD Million)
Table 80. World Urokinase Injection Average Price by Application (2021-2026) & (US$/Unit)
Table 81. World Urokinase Injection Average Price by Application (2027-2032) & (US$/Unit)
Table 82. Syner-Med Basic Information, Manufacturing Base and Competitors
Table 83. Syner-Med Major Business
Table 84. Syner-Med Urokinase Injection Product and Services
Table 85. Syner-Med Urokinase Injection Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 86. Syner-Med Recent Developments/Updates
Table 87. Syner-Med Competitive Strengths & Weaknesses
Table 88. Wanhua Biochem Basic Information, Manufacturing Base and Competitors
Table 89. Wanhua Biochem Major Business
Table 90. Wanhua Biochem Urokinase Injection Product and Services
Table 91. Wanhua Biochem Urokinase Injection Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 92. Wanhua Biochem Recent Developments/Updates
Table 93. Wanhua Biochem Competitive Strengths & Weaknesses
Table 94. Jiangxi Haoran Bio-Pharma Basic Information, Manufacturing Base and Competitors
Table 95. Jiangxi Haoran Bio-Pharma Major Business
Table 96. Jiangxi Haoran Bio-Pharma Urokinase Injection Product and Services
Table 97. Jiangxi Haoran Bio-Pharma Urokinase Injection Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 98. Jiangxi Haoran Bio-Pharma Recent Developments/Updates
Table 99. Jiangxi Haoran Bio-Pharma Competitive Strengths & Weaknesses
Table 100. Jiangsu Aidea Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 101. Jiangsu Aidea Pharmaceutical Major Business
Table 102. Jiangsu Aidea Pharmaceutical Urokinase Injection Product and Services
Table 103. Jiangsu Aidea Pharmaceutical Urokinase Injection Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 104. Jiangsu Aidea Pharmaceutical Recent Developments/Updates
Table 105. Jiangsu Aidea Pharmaceutical Competitive Strengths & Weaknesses
Table 106. Techpool Basic Information, Manufacturing Base and Competitors
Table 107. Techpool Major Business
Table 108. Techpool Urokinase Injection Product and Services
Table 109. Techpool Urokinase Injection Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 110. Techpool Recent Developments/Updates
Table 111. Techpool Competitive Strengths & Weaknesses
Table 112. Microbic Biosystems Basic Information, Manufacturing Base and Competitors
Table 113. Microbic Biosystems Major Business
Table 114. Microbic Biosystems Urokinase Injection Product and Services
Table 115. Microbic Biosystems Urokinase Injection Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 116. Microbic Biosystems Recent Developments/Updates
Table 117. Microbic Biosystems Competitive Strengths & Weaknesses
Table 118. LIVZON Basic Information, Manufacturing Base and Competitors
Table 119. LIVZON Major Business
Table 120. LIVZON Urokinase Injection Product and Services
Table 121. LIVZON Urokinase Injection Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 122. LIVZON Recent Developments/Updates
Table 123. LIVZON Competitive Strengths & Weaknesses
Table 124. Wuhan Humanwell Pharma Basic Information, Manufacturing Base and Competitors
Table 125. Wuhan Humanwell Pharma Major Business
Table 126. Wuhan Humanwell Pharma Urokinase Injection Product and Services
Table 127. Wuhan Humanwell Pharma Urokinase Injection Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 128. Wuhan Humanwell Pharma Recent Developments/Updates
Table 129. Wuhan Humanwell Pharma Competitive Strengths & Weaknesses
Table 130. Tianjin Biochem Pharma Basic Information, Manufacturing Base and Competitors
Table 131. Tianjin Biochem Pharma Major Business
Table 132. Tianjin Biochem Pharma Urokinase Injection Product and Services
Table 133. Tianjin Biochem Pharma Urokinase Injection Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 134. Tianjin Biochem Pharma Recent Developments/Updates
Table 135. Tianjin Biochem Pharma Competitive Strengths & Weaknesses
Table 136. Global Key Players of Urokinase Injection Upstream (Raw Materials)
Table 137. Global Urokinase Injection Typical Customers
Table 138. Urokinase Injection Typical Distributors
Table 1. World Urokinase Injection Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Urokinase Injection Production Value by Region (2021-2026) & (USD Million)
Table 3. World Urokinase Injection Production Value by Region (2027-2032) & (USD Million)
Table 4. World Urokinase Injection Production Value Market Share by Region (2021-2026)
Table 5. World Urokinase Injection Production Value Market Share by Region (2027-2032)
Table 6. World Urokinase Injection Production by Region (2021-2026) & (K Units)
Table 7. World Urokinase Injection Production by Region (2027-2032) & (K Units)
Table 8. World Urokinase Injection Production Market Share by Region (2021-2026)
Table 9. World Urokinase Injection Production Market Share by Region (2027-2032)
Table 10. World Urokinase Injection Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World Urokinase Injection Average Price by Region (2027-2032) & (US$/Unit)
Table 12. Urokinase Injection Major Market Trends
Table 13. World Urokinase Injection Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World Urokinase Injection Consumption by Region (2021-2026) & (K Units)
Table 15. World Urokinase Injection Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World Urokinase Injection Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Urokinase Injection Producers in 2025
Table 18. World Urokinase Injection Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key Urokinase Injection Producers in 2025
Table 20. World Urokinase Injection Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global Urokinase Injection Company Evaluation Quadrant
Table 22. World Urokinase Injection Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Urokinase Injection Production Site of Key Manufacturer
Table 24. Urokinase Injection Market: Company Product Type Footprint
Table 25. Urokinase Injection Market: Company Product Application Footprint
Table 26. Urokinase Injection Competitive Factors
Table 27. Urokinase Injection New Entrant and Capacity Expansion Plans
Table 28. Urokinase Injection Mergers & Acquisitions Activity
Table 29. United States VS China Urokinase Injection Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Urokinase Injection Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China Urokinase Injection Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based Urokinase Injection Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Urokinase Injection Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Urokinase Injection Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Urokinase Injection Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers Urokinase Injection Production Market Share (2021-2026)
Table 37. China Based Urokinase Injection Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Urokinase Injection Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Urokinase Injection Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Urokinase Injection Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers Urokinase Injection Production Market Share (2021-2026)
Table 42. Rest of World Based Urokinase Injection Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Urokinase Injection Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Urokinase Injection Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Urokinase Injection Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers Urokinase Injection Production Market Share (2021-2026)
Table 47. World Urokinase Injection Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Urokinase Injection Production by Type (2021-2026) & (K Units)
Table 49. World Urokinase Injection Production by Type (2027-2032) & (K Units)
Table 50. World Urokinase Injection Production Value by Type (2021-2026) & (USD Million)
Table 51. World Urokinase Injection Production Value by Type (2027-2032) & (USD Million)
Table 52. World Urokinase Injection Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World Urokinase Injection Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World Urokinase Injection Production Value by Clinical Use, (USD Million), 2021 & 2025 & 2032
Table 55. World Urokinase Injection Production by Clinical Use (2021-2026) & (K Units)
Table 56. World Urokinase Injection Production by Clinical Use (2027-2032) & (K Units)
Table 57. World Urokinase Injection Production Value by Clinical Use (2021-2026) & (USD Million)
Table 58. World Urokinase Injection Production Value by Clinical Use (2027-2032) & (USD Million)
Table 59. World Urokinase Injection Average Price by Clinical Use (2021-2026) & (US$/Unit)
Table 60. World Urokinase Injection Average Price by Clinical Use (2027-2032) & (US$/Unit)
Table 61. World Urokinase Injection Production Value by Administration Approach, (USD Million), 2021 & 2025 & 2032
Table 62. World Urokinase Injection Production by Administration Approach (2021-2026) & (K Units)
Table 63. World Urokinase Injection Production by Administration Approach (2027-2032) & (K Units)
Table 64. World Urokinase Injection Production Value by Administration Approach (2021-2026) & (USD Million)
Table 65. World Urokinase Injection Production Value by Administration Approach (2027-2032) & (USD Million)
Table 66. World Urokinase Injection Average Price by Administration Approach (2021-2026) & (US$/Unit)
Table 67. World Urokinase Injection Average Price by Administration Approach (2027-2032) & (US$/Unit)
Table 68. World Urokinase Injection Production Value by Purity, (USD Million), 2021 & 2025 & 2032
Table 69. World Urokinase Injection Production by Purity (2021-2026) & (K Units)
Table 70. World Urokinase Injection Production by Purity (2027-2032) & (K Units)
Table 71. World Urokinase Injection Production Value by Purity (2021-2026) & (USD Million)
Table 72. World Urokinase Injection Production Value by Purity (2027-2032) & (USD Million)
Table 73. World Urokinase Injection Average Price by Purity (2021-2026) & (US$/Unit)
Table 74. World Urokinase Injection Average Price by Purity (2027-2032) & (US$/Unit)
Table 75. World Urokinase Injection Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 76. World Urokinase Injection Production by Application (2021-2026) & (K Units)
Table 77. World Urokinase Injection Production by Application (2027-2032) & (K Units)
Table 78. World Urokinase Injection Production Value by Application (2021-2026) & (USD Million)
Table 79. World Urokinase Injection Production Value by Application (2027-2032) & (USD Million)
Table 80. World Urokinase Injection Average Price by Application (2021-2026) & (US$/Unit)
Table 81. World Urokinase Injection Average Price by Application (2027-2032) & (US$/Unit)
Table 82. Syner-Med Basic Information, Manufacturing Base and Competitors
Table 83. Syner-Med Major Business
Table 84. Syner-Med Urokinase Injection Product and Services
Table 85. Syner-Med Urokinase Injection Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 86. Syner-Med Recent Developments/Updates
Table 87. Syner-Med Competitive Strengths & Weaknesses
Table 88. Wanhua Biochem Basic Information, Manufacturing Base and Competitors
Table 89. Wanhua Biochem Major Business
Table 90. Wanhua Biochem Urokinase Injection Product and Services
Table 91. Wanhua Biochem Urokinase Injection Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 92. Wanhua Biochem Recent Developments/Updates
Table 93. Wanhua Biochem Competitive Strengths & Weaknesses
Table 94. Jiangxi Haoran Bio-Pharma Basic Information, Manufacturing Base and Competitors
Table 95. Jiangxi Haoran Bio-Pharma Major Business
Table 96. Jiangxi Haoran Bio-Pharma Urokinase Injection Product and Services
Table 97. Jiangxi Haoran Bio-Pharma Urokinase Injection Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 98. Jiangxi Haoran Bio-Pharma Recent Developments/Updates
Table 99. Jiangxi Haoran Bio-Pharma Competitive Strengths & Weaknesses
Table 100. Jiangsu Aidea Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 101. Jiangsu Aidea Pharmaceutical Major Business
Table 102. Jiangsu Aidea Pharmaceutical Urokinase Injection Product and Services
Table 103. Jiangsu Aidea Pharmaceutical Urokinase Injection Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 104. Jiangsu Aidea Pharmaceutical Recent Developments/Updates
Table 105. Jiangsu Aidea Pharmaceutical Competitive Strengths & Weaknesses
Table 106. Techpool Basic Information, Manufacturing Base and Competitors
Table 107. Techpool Major Business
Table 108. Techpool Urokinase Injection Product and Services
Table 109. Techpool Urokinase Injection Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 110. Techpool Recent Developments/Updates
Table 111. Techpool Competitive Strengths & Weaknesses
Table 112. Microbic Biosystems Basic Information, Manufacturing Base and Competitors
Table 113. Microbic Biosystems Major Business
Table 114. Microbic Biosystems Urokinase Injection Product and Services
Table 115. Microbic Biosystems Urokinase Injection Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 116. Microbic Biosystems Recent Developments/Updates
Table 117. Microbic Biosystems Competitive Strengths & Weaknesses
Table 118. LIVZON Basic Information, Manufacturing Base and Competitors
Table 119. LIVZON Major Business
Table 120. LIVZON Urokinase Injection Product and Services
Table 121. LIVZON Urokinase Injection Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 122. LIVZON Recent Developments/Updates
Table 123. LIVZON Competitive Strengths & Weaknesses
Table 124. Wuhan Humanwell Pharma Basic Information, Manufacturing Base and Competitors
Table 125. Wuhan Humanwell Pharma Major Business
Table 126. Wuhan Humanwell Pharma Urokinase Injection Product and Services
Table 127. Wuhan Humanwell Pharma Urokinase Injection Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 128. Wuhan Humanwell Pharma Recent Developments/Updates
Table 129. Wuhan Humanwell Pharma Competitive Strengths & Weaknesses
Table 130. Tianjin Biochem Pharma Basic Information, Manufacturing Base and Competitors
Table 131. Tianjin Biochem Pharma Major Business
Table 132. Tianjin Biochem Pharma Urokinase Injection Product and Services
Table 133. Tianjin Biochem Pharma Urokinase Injection Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 134. Tianjin Biochem Pharma Recent Developments/Updates
Table 135. Tianjin Biochem Pharma Competitive Strengths & Weaknesses
Table 136. Global Key Players of Urokinase Injection Upstream (Raw Materials)
Table 137. Global Urokinase Injection Typical Customers
Table 138. Urokinase Injection Typical Distributors
LIST OF FIGURES
Figure 1. Urokinase Injection Picture
Figure 2. World Urokinase Injection Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Urokinase Injection Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Urokinase Injection Production (2021-2032) & (K Units)
Figure 5. World Urokinase Injection Average Price (2021-2032) & (US$/Unit)
Figure 6. World Urokinase Injection Production Value Market Share by Region (2021-2032)
Figure 7. World Urokinase Injection Production Market Share by Region (2021-2032)
Figure 8. North America Urokinase Injection Production (2021-2032) & (K Units)
Figure 9. Europe Urokinase Injection Production (2021-2032) & (K Units)
Figure 10. China Urokinase Injection Production (2021-2032) & (K Units)
Figure 11. Japan Urokinase Injection Production (2021-2032) & (K Units)
Figure 12. Urokinase Injection Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Urokinase Injection Consumption (2021-2032) & (K Units)
Figure 15. World Urokinase Injection Consumption Market Share by Region (2021-2032)
Figure 16. United States Urokinase Injection Consumption (2021-2032) & (K Units)
Figure 17. China Urokinase Injection Consumption (2021-2032) & (K Units)
Figure 18. Europe Urokinase Injection Consumption (2021-2032) & (K Units)
Figure 19. Japan Urokinase Injection Consumption (2021-2032) & (K Units)
Figure 20. South Korea Urokinase Injection Consumption (2021-2032) & (K Units)
Figure 21. ASEAN Urokinase Injection Consumption (2021-2032) & (K Units)
Figure 22. India Urokinase Injection Consumption (2021-2032) & (K Units)
Figure 23. Producer Shipments of Urokinase Injection by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Urokinase Injection Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Urokinase Injection Markets in 2025
Figure 26. United States VS China: Urokinase Injection Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Urokinase Injection Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Urokinase Injection Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Urokinase Injection Production Market Share 2025
Figure 30. China Based Manufacturers Urokinase Injection Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Urokinase Injection Production Market Share 2025
Figure 32. World Urokinase Injection Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 33. World Urokinase Injection Production Value Market Share by Type in 2025
Figure 34. 10000-100000IU
Figure 35. 100000-1000000IU
Figure 36. Others
Figure 37. World Urokinase Injection Production Market Share by Type (2021-2032)
Figure 38. World Urokinase Injection Production Value Market Share by Type (2021-2032)
Figure 39. World Urokinase Injection Average Price by Type (2021-2032) & (US$/Unit)
Figure 40. World Urokinase Injection Production Value by Clinical Use, (USD Million), 2021 & 2025 & 2032
Figure 41. World Urokinase Injection Production Value Market Share by Clinical Use in 2025
Figure 42. Pulmonary Embolism Thrombolysis
Figure 43. Deep Vein Thrombosis
Figure 44. Peripheral Arterial Occlusion Thrombolysis
Figure 45. Catheter / Cannula Occlusion Clearance
Figure 46. Others
Figure 47. World Urokinase Injection Production Market Share by Clinical Use (2021-2032)
Figure 48. World Urokinase Injection Production Value Market Share by Clinical Use (2021-2032)
Figure 49. World Urokinase Injection Average Price by Clinical Use (2021-2032) & (US$/Unit)
Figure 50. World Urokinase Injection Production Value by Administration Approach, (USD Million), 2021 & 2025 & 2032
Figure 51. World Urokinase Injection Production Value Market Share by Administration Approach in 2025
Figure 52. Systemic Infusion
Figure 53. Catheter-directed Thrombolysis (CDT)
Figure 54. Intracatheter Dwell / Lock Technique
Figure 55. World Urokinase Injection Production Market Share by Administration Approach (2021-2032)
Figure 56. World Urokinase Injection Production Value Market Share by Administration Approach (2021-2032)
Figure 57. World Urokinase Injection Average Price by Administration Approach (2021-2032) & (US$/Unit)
Figure 58. World Urokinase Injection Production Value by Purity, (USD Million), 2021 & 2025 & 2032
Figure 59. World Urokinase Injection Production Value Market Share by Purity in 2025
Figure 60. Standard Clinical Grade
Figure 61. High-purity / Low-impurity Grade
Figure 62. Low Endotoxin / Low Bioburden Specifications
Figure 63. World Urokinase Injection Production Market Share by Purity (2021-2032)
Figure 64. World Urokinase Injection Production Value Market Share by Purity (2021-2032)
Figure 65. World Urokinase Injection Average Price by Purity (2021-2032) & (US$/Unit)
Figure 66. World Urokinase Injection Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 67. World Urokinase Injection Production Value Market Share by Application in 2025
Figure 68. Hospital
Figure 69. Clinic
Figure 70. Others
Figure 71. World Urokinase Injection Production Market Share by Application (2021-2032)
Figure 72. World Urokinase Injection Production Value Market Share by Application (2021-2032)
Figure 73. World Urokinase Injection Average Price by Application (2021-2032) & (US$/Unit)
Figure 74. Urokinase Injection Industry Chain
Figure 75. Urokinase Injection Procurement Model
Figure 76. Urokinase Injection Sales Model
Figure 77. Urokinase Injection Sales Channels, Direct Sales, and Distribution
Figure 78. Methodology
Figure 79. Research Process and Data Source
Figure 1. Urokinase Injection Picture
Figure 2. World Urokinase Injection Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Urokinase Injection Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Urokinase Injection Production (2021-2032) & (K Units)
Figure 5. World Urokinase Injection Average Price (2021-2032) & (US$/Unit)
Figure 6. World Urokinase Injection Production Value Market Share by Region (2021-2032)
Figure 7. World Urokinase Injection Production Market Share by Region (2021-2032)
Figure 8. North America Urokinase Injection Production (2021-2032) & (K Units)
Figure 9. Europe Urokinase Injection Production (2021-2032) & (K Units)
Figure 10. China Urokinase Injection Production (2021-2032) & (K Units)
Figure 11. Japan Urokinase Injection Production (2021-2032) & (K Units)
Figure 12. Urokinase Injection Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Urokinase Injection Consumption (2021-2032) & (K Units)
Figure 15. World Urokinase Injection Consumption Market Share by Region (2021-2032)
Figure 16. United States Urokinase Injection Consumption (2021-2032) & (K Units)
Figure 17. China Urokinase Injection Consumption (2021-2032) & (K Units)
Figure 18. Europe Urokinase Injection Consumption (2021-2032) & (K Units)
Figure 19. Japan Urokinase Injection Consumption (2021-2032) & (K Units)
Figure 20. South Korea Urokinase Injection Consumption (2021-2032) & (K Units)
Figure 21. ASEAN Urokinase Injection Consumption (2021-2032) & (K Units)
Figure 22. India Urokinase Injection Consumption (2021-2032) & (K Units)
Figure 23. Producer Shipments of Urokinase Injection by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Urokinase Injection Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Urokinase Injection Markets in 2025
Figure 26. United States VS China: Urokinase Injection Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Urokinase Injection Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Urokinase Injection Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Urokinase Injection Production Market Share 2025
Figure 30. China Based Manufacturers Urokinase Injection Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Urokinase Injection Production Market Share 2025
Figure 32. World Urokinase Injection Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 33. World Urokinase Injection Production Value Market Share by Type in 2025
Figure 34. 10000-100000IU
Figure 35. 100000-1000000IU
Figure 36. Others
Figure 37. World Urokinase Injection Production Market Share by Type (2021-2032)
Figure 38. World Urokinase Injection Production Value Market Share by Type (2021-2032)
Figure 39. World Urokinase Injection Average Price by Type (2021-2032) & (US$/Unit)
Figure 40. World Urokinase Injection Production Value by Clinical Use, (USD Million), 2021 & 2025 & 2032
Figure 41. World Urokinase Injection Production Value Market Share by Clinical Use in 2025
Figure 42. Pulmonary Embolism Thrombolysis
Figure 43. Deep Vein Thrombosis
Figure 44. Peripheral Arterial Occlusion Thrombolysis
Figure 45. Catheter / Cannula Occlusion Clearance
Figure 46. Others
Figure 47. World Urokinase Injection Production Market Share by Clinical Use (2021-2032)
Figure 48. World Urokinase Injection Production Value Market Share by Clinical Use (2021-2032)
Figure 49. World Urokinase Injection Average Price by Clinical Use (2021-2032) & (US$/Unit)
Figure 50. World Urokinase Injection Production Value by Administration Approach, (USD Million), 2021 & 2025 & 2032
Figure 51. World Urokinase Injection Production Value Market Share by Administration Approach in 2025
Figure 52. Systemic Infusion
Figure 53. Catheter-directed Thrombolysis (CDT)
Figure 54. Intracatheter Dwell / Lock Technique
Figure 55. World Urokinase Injection Production Market Share by Administration Approach (2021-2032)
Figure 56. World Urokinase Injection Production Value Market Share by Administration Approach (2021-2032)
Figure 57. World Urokinase Injection Average Price by Administration Approach (2021-2032) & (US$/Unit)
Figure 58. World Urokinase Injection Production Value by Purity, (USD Million), 2021 & 2025 & 2032
Figure 59. World Urokinase Injection Production Value Market Share by Purity in 2025
Figure 60. Standard Clinical Grade
Figure 61. High-purity / Low-impurity Grade
Figure 62. Low Endotoxin / Low Bioburden Specifications
Figure 63. World Urokinase Injection Production Market Share by Purity (2021-2032)
Figure 64. World Urokinase Injection Production Value Market Share by Purity (2021-2032)
Figure 65. World Urokinase Injection Average Price by Purity (2021-2032) & (US$/Unit)
Figure 66. World Urokinase Injection Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 67. World Urokinase Injection Production Value Market Share by Application in 2025
Figure 68. Hospital
Figure 69. Clinic
Figure 70. Others
Figure 71. World Urokinase Injection Production Market Share by Application (2021-2032)
Figure 72. World Urokinase Injection Production Value Market Share by Application (2021-2032)
Figure 73. World Urokinase Injection Average Price by Application (2021-2032) & (US$/Unit)
Figure 74. Urokinase Injection Industry Chain
Figure 75. Urokinase Injection Procurement Model
Figure 76. Urokinase Injection Sales Model
Figure 77. Urokinase Injection Sales Channels, Direct Sales, and Distribution
Figure 78. Methodology
Figure 79. Research Process and Data Source
